Peficitinib, a JAK Inhibitor, in Combination with Limited Conventional Synthetic DMARDs in the Treatment of Moderate-to-severe Rheumatoid Arthritis
Arthritis Rheumatol DOI 10.1002/art.40054. Accepted article.
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Arthritis Rheumatol DOI 10.1002/art.40054. Accepted article.
Ann Rheum Dis 2017;76:88–95.
Arthritis Rheumatol 2017. DOI 10.1002/art.40036.
J Rheumatol 2017;44:2. DOI 10.3899/jrheum.160287.
J Manag Care Spec Pharm. 2016 Dec;22(12):1457-1471.
J Am Acad Dermatol 2017;76:405–17. doi: 10.1016/j.jaad.2016.11.041
Guselkumab demonstrated superiority to adalimumab and placebo in treating PsO in this Phase 3 study. Improvements in IGA and PASI scores were observed as early as Week 16 and were maintained up to Week 48. Incidence of adverse events was similar across both treatment groups.
J Am Acad Dermatol 2017;76:418–31. doi: 10.1016/j.jaad.2016.11.042
Patients treated with guselkumab showed an improved and sustained clinical response compared to both adalimumab and placebo, without compromising safety profile. The Phase 3 VOYAGE 2 trial by Reich et al focused on treatment interruption and withdrawal, as well as treatment switching from adalimumab to guselkumab.
Clin Ther 2016;38:2628–40.
Cochrane Database Syst Rev 2016;11:CD012437.
Arthritis Rheumatol 2016. DOI:10.1002/art.39944.